Development of a new targeted anticancer treatment for Adolescent and Young Adult refractory soft tissue sarcoma

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K07753
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Sapporo Medical University
• Principal Investigator: Murase Kazuyuki 札幌医科大学, 医学部, 講師 (90444918)
• Co-Investigator(Kenkyū-buntansha): 加藤 淳二 札幌医科大学, 医学部, 教授 (20244345) ; 高田 弘一 札幌医科大学, 医学部, 講師 (90398321)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 難治性軟部肉腫 / 標的抗がん治療法

Outline of Final Research Achievements

Development of a new treatment method is desired to improve the prognosis of advanced soft tissue sarcoma, which is a problem in the Adolescent and Young Adult generation. In this study, we investigated the BH3 profiling and drug delivery system to clarify the anticancer drug susceptibility by a new reagent to soft tissue sarcoma using liposome bound with Fluorodeoxyglucose (FDG). This clarified the therapeutic and synergistic effects of various anticancer agents in soft tissue sarcoma.

Free Research Field

臨床腫瘍

Academic Significance and Societal Importance of the Research Achievements

AYA世代で問題となる進行軟部肉腫の予後改善のため、新規治療法の開発が望まれている。本研究で検討したFluorodeoxyglucose (FDG)を結合したLiposomeを使用した軟部肉腫に対する新たなDDSは、軟部肉腫における新規治療法の可能性があるが、更なる改良・検討を要する課題であった。